Skip to content
RxMonitor home

Medication

Nra-Amlodipine

DIN 02476479 · Nora Pharma Inc Likely a generic

What it is

Active ingredients
Form and route
Tablet · Oral
Schedule
PRESCRIPTION
Authorised since
2018-11-27

Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.

Products with the same active ingredient

Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.

Watch this medication

Ontario Drug Benefit coverage

As of 31 July 2026

General benefit Part III-A

Ontario lists this product as a general benefit under the Ontario Drug Benefit program — Part III-A of the Formulary/CDI. For someone eligible for ODB, it is covered without a drug-specific approval.

What ODB pays per unit
$0.1993

This is what the Ontario Drug Benefit program reimburses a pharmacy for one unit, as of 31 July 2026. A deductible and a co-payment sit on top of it and differ by program — ODB, the Trillium Drug Program and the seniors co-payment each work differently — so it is not the figure anyone is charged at a counter. It also says nothing about private, workplace or federal coverage.

Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.

Products Ontario considers interchangeable

As of 31 July 2026

Ontario groups these products together at 10mg Tab and will substitute one for another at a pharmacy counter in Ontario.

Ontario lists 5 further products in this group that are not currently marketed in Canada. They are not shown.

This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.

Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.

How it is classified

Anatomical main group
Cardiovascular system
ATC code
C08CA01

The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of C08CA01, see the WHO ATC/DDD Index.

Recalls and safety alerts

As of 12 August 2026
Recall:

Health Canada has published a recall or safety alert naming this product. Read it on Health Canada’s own site, and speak to a pharmacist before changing anything about how you take this medication.

  • NRA-AMLODIPINE 5MG: Affected lot may contain tablet(s) of Metoprolol Succinate prolonged–release 12.5 mg tablets

    8 July 2025Product safetyType I

    Health Canada says: Check your medication bottle to ensure it only contains NRA-AMLODIPINE 5 mg tablets.If your bottle contains any round tablets, which are not the correct shape, or if you're unsure, return the bottle to your pharmacy for a replacement.If you are unable to get a replacement immediately, continue to take your medication as directed, but do not take the round tablets as these are the wrong medication.Contact your health care professional if you are dizzy, have unusually low blood pressure or slow heartbeats. If you are unable to access a health care professional and you are experiencing these symptoms, call 911.If you have questions about this recall, contact Nora Pharma Inc. by calling their Quality Assurance Department at 450-904-2355 or by emailing info@norapharma.ca.Report any health product-related side effects or complaints to Health Canada.Additional information for health professionals:Health care professionals, such as pharmacists, should check packages and bottles labelled NRA-AMLODIPINE 5 mg (amlodipine besylate) before dispensing to make sure they do not contain Metoprolol Succinate prolonged-release 12.5 mg tablets. Report any unusual bottles or other issues to the company and Health Canada.

    Matched on the product name at the start of the notice.

This list may be incomplete. Health Canada’s recalls data carries no DIN, so notices are matched on wording alone. Search Health Canada recalls for Nra-Amlodipine How RxMonitor matches recalls, and how often it fails

Source: Health Canada — Recalls and Safety Alerts. Data current as of 2026-08-12. Matched on product name, not on DIN — the feed carries none.

Important:

Information only — this is not medical advice. RxMonitor shows what Health Canada and provincial drug programs have published about authorised products. It does not tell you what to take, whether a medication is right for you, or what dose to use.

Always talk to a pharmacist or physician about your own medication, and never start, stop or change one based on what you read here.